Cargando…
Anlotinib Combined with S‐1 in Third‐ or Later‐Line Stage IV Non‐Small Cell Lung Cancer Treatment: A Phase II Clinical Trial
LESSONS LEARNED: The combination of anlotinib and S‐1 exhibited good antitumor activity in third‐ or later‐line treatment for stage IV non‐small cell lung cancer (NSCLC). Combination therapy of anlotinib with S‐1 has manageable toxicities in patients with NSCLC. BACKGROUND: This study aimed to evalu...
Autores principales: | Xiang, Miao, Yang, Xiyue, Ren, Surong, Du, Huan, Geng, Lidan, Yuan, Li, Wen, Yixue, Lin, Binwei, Li, Jie, Zhang, Yu, Feng, Gang, Du, Xiaobo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649049/ https://www.ncbi.nlm.nih.gov/pubmed/34423518 http://dx.doi.org/10.1002/onco.13950 |
Ejemplares similares
-
Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial
por: Yang, Xiyue, et al.
Publicado: (2019) -
Single‐Agent Versus Double‐Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial
por: Zhao, Zhenhuan, et al.
Publicado: (2020) -
Concurrent EGFR‐TKI and Thoracic Radiotherapy as First‐Line Treatment for Stage IV Non‐Small Cell Lung Cancer Harboring EGFR Active Mutations
por: Zheng, LinPeng, et al.
Publicado: (2019) -
Endogenous Heat‐Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma
por: Domingo‐Musibay, Evidio, et al.
Publicado: (2017) -
Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma
por: Jun, Tomi, et al.
Publicado: (2022)